Off-Label Use

Deep dive

Off-Label Use: complete reference

Off-label prescribing refers to using an FDA-approved medication для a purpose, dose, or population not specified в the FDA-approved labeling. Off-label use is LEGAL — physicians have prescribing discretion based on clinical judgment + evidence — but is NOT FDA-endorsed and may have insurance coverage implications. Common GLP-1 off-label scenarios: Ozempic/Mounjaro prescribed для weight loss (FDA-approved для T2D only), Rybelsus prescribed для weight management, GLP-1s prescribed для prediabetes (no specific approval). Off-label use historically was easier to get insurance coverage for, but in 2026 insurance plans increasingly audit off-label claims — patients with Mounjaro prescriptions без T2D diagnosis face higher denial rates than ever. Risks of off-label use: no FDA review of efficacy/safety для that specific use, no manufacturer marketing support, insurance coverage may be denied или clawed back. Off-label IS legitimate medicine — many standard-of-care practices начались как off-label use — but patient + prescriber should understand the trade-offs.

In practice

Your doctor prescribes Mounjaro для weight loss even though it's FDA-approved only для diabetes. Legal? Yes. Insurance covered? Increasingly no в 2026.

Clinical context

Off-label is legal physician discretion. Insurance increasingly restrictive against off-label coverage в 2026.